References

nodgo

Российский журнал детской гематологии и онкологии (РЖДГиО)

Russian Journal of Pediatric Hematology and Oncology

2311-12672413-5496

LTD “Graphica”

10.21682/2311-1267-2021-8-3-79-85

nodgo-746

Research Article

ОБЗОРЫ ЛИТЕРАТУРЫ

LITERATURE REVIEWS

Обзор фармакогенетических аспектов токсичности метотрексата и 6-меркаптопурина при лечении острого лимфобластного лейкоза у детей

A review of pharmacogenetic aspects of methotrexate and 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia treatment

https://orcid.org/0000-0002-0050-0721

Гурьева

О. Д.

Gurieva

О. D.

Оксана Дмитриевна Гурьева, врач-детский онколог отделения детской онкологии и гематологии (химиотерапия гемобластозов) № 1 НИИ детской онкологии и гематологии

115478, Москва, Каширское шоссе, 23

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Pediatric Oncologist Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1 of the Research Institute of Pediatric Oncology and Hematology

23 Kashirskoe Shosse, Moscow, 115478

Bld. 1, 2/1 Barrikadnaya St., Moscow, 125993

swimmer96ok@gmail.com

https://orcid.org/0000-0002-2373-2250

Савельева

М. И.

Savelyeva

М. I.

д.м.н., профессор кафедры клинической фармакологии и терапии им. акад. Б.Е. Вотчала

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Dr. of Sci. (Med.), Professor at the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal

Bld. 1, 2/1 Barrikadnaya St., Moscow, 125993

marinasavelyeva@mail.ru

https://orcid.org/0000-0002-1469-2365

Валиев

Т. Т.

Valiev

Т. Т.

д.м.н., заведующий отделением детской онкологии и гематологии (химиотерапия гемобластозов) № 1 НИИ детской онкологии и гематологии; профессор кафедры детской онкологии им. акад. Л.А. Дурнова

115478, Москва, Каширское шоссе, 23

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Dr. of Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1 of the Research Institute of Pediatric Oncology and Hematology; Professor at the Department of Pediatric Oncology named after Academician L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115478

Bld. 1, 2/1 Barrikadnaya St., Moscow, 125993

timurvaliev@mail.ru

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education, Ministry of Health of RussiaRussian Federation

ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional Education, Ministry of Health of RussiaRussian Federation

2021

18102021

837985

2021

Гурьева О.Д., Савельева М.И., Валиев Т.Т.

Gurieva О.D., Savelyeva М.I., Valiev Т.Т.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nodgo.org/jour/article/view/746

Существенный прогресс в лечении острого лимфобластного лейкоза (ОЛЛ) у детей произошел в результате разработки эффективных протоколов химио- и сопроводительной терапии. Вектор дальнейших исследований направлен на снижение токсичности и отдаленных побочных эффектов. Изучение фармакогенетических (ФГ) аспектов токсичности одних из основных препаратов, используемых в лечении ОЛЛ, – метотрексата и 6-меркаптопурина – позволил выявить олигонуклеотидные полиморфизмы, коррелирующие с концентрацией препарата в крови, токсическими эффектами и риском рецидива ОЛЛ.Клиническое применение ФГ-методов остается сложной задачей, требующей дополнительных исследований, в результате которых возможно будет индивидуализировать терапию ОЛЛ на основании результатов молекулярного профилирования.

Significant progress in the treatment of acute lymphoblastic leukemia (ALL) in children has resulted from the development of effective chemoand supportive care therapy protocols. The vector of further research is aimed at reducing toxicity and long-term side effects. The study of pharmacogenetic aspects of toxicity of the main drugs used in the treatment of ALL – methotrexate and 6-mercaptopurine – allowed to identify oligonucleotide polymorphisms that correlate with the concentration of the drug in blood, toxic effects and the risk of relapse of ALL. The clinical administration of pharmacogenetic methods remains a challenging task, requiring additional research, which will make it possible to individualize the ALL therapy on the basis of the results of molecular profiling.

острый лимфобластный лейкозметотрексат6-меркаптопуринлечениетоксичностьфармакогенетикадети

acute lymphoblastic leukemiamethotrexate6-mercaptopurinetreatmenttoxicitypharmacogeneticschildren

References1

Demidowicz E., Pogorzała M., Łęcka M., Żołnowska H., Marjańska A., Kubicka M., Kuryło-Rafińska B., Czyżewski K., Dębski R., Kołtan A., Richert-Przygońska M., Styczyński J. Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. Anticancer Res 2019;39(9):5203–7. doi: 10.21873/anticanres.13717

Maamari D., El-Khoury H., Saifi O., Muwakkit S.A., Zgheib N.K. Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia. Pharmgenomics Pers Med 2020;13:295–317. doi: 10.2147/PGPM.S239602.

Шервашидзе М.А., Валиев Т.Т. Совершенствование программ терапии острого лимфобластного лейкоза у детей: акцент на минимальную остаточную болезнь. Онкогематология 2020;15(3):12–26. doi: 10.17650/1818-8346-2020-15-3-12-26. [Shervashidze M.A., Valiev T.T. Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease. Onkohematolohyya = Oncohematology 2020;15(3):12–26. (In Russ.)].

Пшонкин А.В., Румянцева Ю.В., Литвинов Д.В., Карелин А.Ф., Бойченко Э.Г., Лагойко С.Н., Быданов О.И., Жарикова Л.И., Алейникова О.В., Тютикова Е.С., Дигоева М.А., Аракаев О.Р., Стренева О.В., Шамардина А.В., Шарапова Г.Р., Мякова Н.В., Пономарева Н.И., Хачатрян Л.А., Кондратчик К.Л., Мансурова Е.Г., Минкина Л.М., Ольшанская Ю.В., Юдина Н.Б., Гербек И.Э., Шапочник А.П., Карачунский А.И. Лечение острого лимфобластного лейкоза у подростков и молодых взрослых: опыт Москва– Берлин. Российский журнал детской гематологии и онкологии 2016;3(1):35–43. doi: 10.17650/2311-1267-2016-3-1-35-43. [Pshonkin A.V., Rumyantseva Yu.V., Litvinov D.V., Karelin A.F., Boychenko E.G., Lagoyko S.N., Bydanov O.I., Zharikova L.I., Aleynikova O.V., Tyutikova Y.S., Digoeva M.A., Arakaev O.R., Streneva O.V., Shamardina A.V., Sharapova G.R., Myakova N.V., Ponomareva N.I., Khachatryan I.A., Kondratchik K.L., Mansurova Y.G., Minkina L.M., Olshanskaya Yu.V., Yudina N.B., Gerbek I.E., Shapochnik A.P., Karachunskiy A.I. Treatment of acute lymphoblastic leukemia in adolescents and young adults: the experience of the Moscow–Berlin. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2016;3(1):35–43. (In Russ.)].

Mei L., Ontiveros E.P., Griffiths E.A., Thompson J.E., Wang E.S., Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev 2015;29(4):243–9. doi: 10.1016/j.blre.2015.01.001.

Rudin S., Marable M., Huang R.S. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics 2017;15(2):82–93. doi: 10.1016/j.gpb.2016.11.003.

Gorlick R., Goker E., Trippett T., Waltham M., Banerjee D., Bertino J.R. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335(14):1041–8. doi: 10.1056/NEJM199610033351408.

Kotur N., Lazic J., Ristivojevic B., Stankovic B., Gasic V., Dokmanovic L., Krstovski N., Milosevic G., Janic D., Zukic B., Pavlovic S. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment. Genes (Basel) 2020;11(4):468. doi: 10.3390/genes11040468.

Schulte R.R., Choi L., Utreja N., Van Driest S.L., Stein C.M., Ho R.H. Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma. Clin Transl Sci 2021;14(1):343–53. doi: 10.1111/cts.12879.

Сингин А.С. Популяционная фармакокинетика препарата метотрексат. Клинический мониторинг при лечении острого лимфобластного лейкоза и лимфом у детей. Клиническая фармакокинетика 2004;(1):40–2. [Singin A. S. Population pharmacokinetics of the drug methotrexate. Clinical monitoring in the treatment of acute lymphoblastic leukemia and lymphoma in children. Klinicheskaya farmakokinetika = Clinical Pharmacokinetics 2004;(1):40–2. (In Russ.)].

Laverdière C., Chiasson S., Costea I., Moghrabi A., Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100(10):3832–4. doi: 10.1182/blood.V100.10.383.

Lopez-Lopez E., Ballesteros J., Piñan M.A., de Toledo J.S., de Andoin N.G., Garcia-Miguel P., Navajas A., Garcia-Orad A. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 2013;23(2):53–61. doi: 10.1097/FPC.0b013e32835c3b24.

Radtke S., Zolk O., Renner B., Paulides M., Zimmermann M., Möricke A., Stanulla M., Schrappe M., Langer T. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 2013;121(26):5145–53. doi: 10.1182/blood-2013-01-480335.

Hu Y.H., Zhou L., Wang S.S., Jing X., Guo H.L., Sun F., Zhang, Y., Chen F., Xu J., Ji X. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters. Curr Pharm Des 2019;25(6):627–34. doi: 10.2174/1381612825666190329141003.

Gervasini G., de Murillo S.G., Jiménez M., de la Maya M.D., Vagace J.M. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia. Gene 2017;628:72–7. doi: 10.1016/j.gene.2017.07.025.

Gervasini G., Mota-Zamorano S. Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia. Curr Drug Metab 2019;20(4):313–30. doi: 10.2174/1389200220666190130161758.

Zgheib N.K., Akra-Ismail M., Aridi C., Mahfouz R., Abboud M.R., Solh H., Muwakkit S.A. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2014;24(8):387–96. doi: 10.1097/FPC.0000000000000069.

Treviño L.R., Shimasaki N., Yang W., Panetta J.C., Cheng C., Pei D., Chan D., Sparreboom A., Giacomini K.M., Pui C.H., Evans W.E., Relling M.V. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27(35):5972–8. doi: 10.1200/JCO.2008.20.4156.

Schulte R.R., Choi L., Utreja N., Van Driest S.L., Stein C.M., Ho R.H. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma. Clin Transl Sci 2021;14(1):343–53. doi: 10.1111/cts.12879.

Lopez-Lopez E., Martin-Guerrero I., Ballesteros J., Piñan M.A., Garcia-Miguel P., Navajas A., Garcia-Orad A. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57(4):612–9. doi: 10.1002/pbc.23074.

Razali R.H., Noorizhab M.N.F., Jamari H., James R.J., Teh K.H., Ibrahim H.M., Teh L.K., Salleh M.Z. Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol 2020;37(3):185–97. doi: 10.1080/08880018.2019.1705949.

Gregers J., Gréen H., Christensen I.J., Dalhoff K., Schroeder H., Carlsen N., Rosthoej S., Lausen B., Schmiegelow K., Peterson C. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J 2015;15(4):372–9. doi: 10.1038/tpj.2014.81.

Cwiklinska M., Czogala M., Kwiecinska K., Madetko-Talowska A., Szafarz M., Pawinska K., Wieczorek A., Klekawka T., Rej M., Stepien K., Halubiec P., Lazarczyk A., Miklusiak K., Bik-Multanowski M., Balwierz W., Skoczen S. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate. Front Pediatr 2020;8:307. doi: 10.3389/fped.2020.00307.

Aplenc R., Thompson J., Han P., La M., Zhao H., Lange B., Rebbeck T. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65(6):2482–7. doi: 10.1158/0008-5472.CAN-04-2606.

Chiusolo P., Reddiconto G., Farina G., Mannocci A., Fiorini A., Palladino M., La Torre G., Fianchi L., Sorà F., Laurenti L., Leone G., Sica S. MTHFR polymorphismsʼ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007;31(12):1669–74. doi: 10.1016/j.leukres.2007.03.028.

Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet 2013;381(9881):1943–55. doi: 10.1016/S0140-6736(12)62187-4.

Liu S.G., Gao C., Zhang R.D., Zhao X.X., Cui L., Li W.J., Chen Z.P., Yue Z.X., Zhang Y.Y., Wu M.Y., Wang J.X., Li Z.G., Zheng H.Y. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget 2017;8(23):37761–72. doi: 10.18632/oncotarget.17781.

Krajinovic M., Costea I., Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002;359(9311):1033–4. doi: 10.1016/S0140-6736(02)08065-0.

Lauten M., Asgedom G., Welte K., Schrappe M., Stanulla M. Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 2003;88(3):353–4. PMID: 12651279.

Iparraguirre L., Gutierrez-Camino A., Umerez M., Martin-Guerrero I., Astigarraga I., Navajas A., Sastre A., de Andoin N.G., Garcia-Orad A. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet Genomics 2016;26(11):517–25. doi: 10.1097/FPC.0000000000000245.

Mishra P.J., Humeniuk R., Mishra P.J., Longo-Sorbello G.S., Banerjee D., Bertino J.R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 2007;104(33):13513–8. doi: 10.1073/pnas.0706217104.

Bhatia S., Landier W., Hageman L., Chen Y., Kim H., Sun C.L., Kornegay N., Evans W.E., Angiolillo A.L., Bostrom B., Casillas J., Lew G., Maloney K.W., Mascarenhas L., Ritchey A.K., Termuhlen A.M., Carroll W.L., Wong F.L., Relling M.V. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Childrenʼs Oncology Group Study. JAMA Oncol 2015;1(3):287–95. doi: 10.1001/jamaoncol.2015.0245.

Bhatia S., Landier W., Hageman L., Sun C-L., Kim H., Kornegay N., Evans W., Bostrom B., Casillas J., Angiolillo A., Lew G., Maloney K., Mascarenhas L., Meza J., Ritchey A., Termuhlen A., Carroll W., Wong F., Relling M. High intra-individual variability in systemic exposure to 6 mercaptopurine (6MP) in children with Acute Lymphoblastic Leukemia (ALL) contributes to ALL relapse: results from a Childrenʼs Oncology Group (COG) Study (AALL03N1). Blood 2013;122:59. doi: 10.1182/blood.V122.21.59.59.

Paugh S.W., Stocco G., McCorkle J.R., Diouf B., Crews K.R., Evans W.E. Cancer pharmacogenomics. Clin Pharmacol Ther 2011;90(3):461–6. doi: 10.1038/clpt.2011.126.

Stocco G., Franca R., Verzegnassi F., Londero M., Rabusin M., Decorti G. Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia. Front Genet 2013;3:309. doi: 10.3389/fgene.2012.00309.

Relling M.V., Schwab M., Whirl-Carrillo M., Suarez-Kurtz G., Pui C.H., Stein C.M., Moyer A.M., Evans W.E., Klein T.E., AntillonKlussmann F.G., Caudle K.E., Kato M., Yeoh A.E.J., Schmiegelow K., Yang J.J. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019;105(5):1095–105. doi: 10.1002/cpt.1304.

Pui C.H., Sandlund J.T., Pei D., Campana D., Rivera G.K., Ribeiro R.C., Rubnitz J.E., Razzouk B.I., Howard S.C., Hudson M.M., Cheng C., Kun L.E., Raimondi S.C., Behm F.G., Downing J.R., Relling M.V., Evans W.E. Total Therapy Study XIIIB at St Jude Childrenʼs Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Childrenʼs Research Hospital. Blood 2004;104(9):2690–6. doi: 10.1182/blood-2004-04-1616.

Adam de Beaumais T., Dervieux T., Fakhoury M., Medard Y., Azougagh S., Zhang D., Yakouben K., Jacqz-Aigrain E. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2010;66(4):653–8. doi: 10.1007/s00280-009-1205-4.

Hoffman J.M., Haidar C.E., Wilkinson M.R., Сrews K.R., Baker D.K., Kornegay N.M., Yang W., Pui C.H., Reiss U.M., Gaur A.H., Howard S.C., Evans W.E., Broeckel U., Relling M.V. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014;166C(1):45–55. doi: 10.1002/ajmg.c.31391.

The authors declare that there are no conflicts of interest present.